Skip to content
DataLookout
Menu

ENHANCENCT07542314

Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting

StatusRecruiting
PhasePhase 4
Primary completion (estimated)

At risk: Primary completion moved 5 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date pushed from Oct 30, 2026 to Nov 30, 2026
    • Study sites: 1 to 2
  2. Notable Recruitment opened Show 4 more changesShow less
    • Start date: Aug 31, 2026 to Oct 30, 2026
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 1 of 9 entries
    • Site details revised
  3. Notable Start date: Jul 31, 2026 to Aug 31, 2026
    • Primary and study completion pushed from Mar 31, 2027 to Aug 31, 2027
    • Study sites: 0 to 1
    v3
  4. Notable Start date: Apr 30, 2026 to Jul 31, 2026v2
  5. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Cohort 1: Number of Participants with ALI
Timeframe: 12 weeks

Secondary (9)

Cohort 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs)
Cohort 1: Number of Participants with Infections, Edema, Wound-healing Complications, Hyperlipidemia, Angioedema, and Interstitial Lung Disease/Non-infectious Pneumonitis
Cohort 1: Number of Participants with Hepatic Adverse Events, Hepatic Biomarkers, and Laboratory Assessments Indicative of Either Acute Hepatocellular Injury or Acute Liver Dysfunction
Cohort 1: Number of Participants with Severe ALI
Cohort 1: Number of Participants with ALI
Show 4 moreShow less
Cohort 1: Duration of ALI
Cohort 1: Amount of Steroid Use
Cohort 1: Duration of Steroid Use
Cohort 1: Quantity of ELEVIDYS Dystrophin Protein Expression as Measured by Western Blot

Arms and interventions

Cohort 1: ELEVIDYSOther

Participants will receive ELEVIDYS in a commercial setting on Day 1. Participants will also receive sirolimus, glucocorticoids and antibiotics orally.

Cohort 2: ELEVIDYSNo intervention

Participants who have previously received ELEVIDYS in a commercial setting after prophylactic treatment with sirolimus and corticosteroids will participate in one study visit during which a muscle biopsy will be performed. No study treatment will be administered in this cohort.

Drugs: ELEVIDYS, Sirolimus, Glucocorticoids, Antibiotics

Sites

2 sites in 1 country